Shop Antibodies
Pembrolizuma Biosimilar Antibody Production

Pembrolizuma Biosimilar Antibody Production

Left: protein sequences of Pembrolizuma are fetched from NCBI and PDB structure databases. Right, top, heavy chain and light chain of Pembrolizuma are cloned into lentivirus and used to infect SP2 mouse hybridoma cells. After clonal selection, supernatants are blotted by anti-human IgG-HRP antibody. Right, bottom, after clonal expansion, cell culture media are subjected to protein A chromatography to manufacture Pembrolizuma in large quantities.

Best Seller

Biosimilar Antibody Production

$950.00 – $17,500.00

Antibody: Monoclonal Antibody

Concentration: 0.25 mg/ml of purified IgG

Application: In vitro and In vivo

Reactivity: Human

BiCell Scientific Inc has developed a robust recombinant expression system to produce human biosimilar antibodies in lentivirus transduced mouse hybridoma cells.

BiCell Scientific Inc’s Biosimilar Antibodies are research-grade human biosimilar monoclonal antibodies. Each biosimilar antibody is produced using recombinant technology in bioreactors and incorporates the same variable region sequence as the original pharmaceutical substance. The Fc domain is offered in four different isotypes: IgG1, IgG2, IgG3 and IgG4.

Biosimilar antibodies make it possible to study the biological effects of a pharmaceutical substance without needing to source expensive pharmaceutical-grade therapeutics. They can be used for many research applications including functional assays, flow cytometry, ELISA, Immunohistochemistry, pharmacokinetic assays, and others.

BiCell Scientific Inc has optimized hybridoma cell growth for monoclonal antibody secretion in continuous cultivation bioreactor with a chemically defined, serum-free culture medium (Cat No: BCMABK6). Continuous cultivation bioreactor permits monoclonal antibody secretion rate to reach 100-150 μg/ml medium, which enables BiCell Scientific Inc to deliver biosimilar antibodies at the gram level.

  • Gene synthesis of therapeutic antibody heavy chain and light chain sequences from NCBI database
  • Molecular cloning of antibody heavy chain and light chain sequences into lentiviral backbone vector
  • Transfection of HEK293T cells with lentiviral backbone vector as well as vectors expressing gag–pol, rev and vsv–g
  • Harvesting and purification of lentivirus from cell culture medium
  • Transducing naive Sp2/0-Ag14 hybridoma cells
  • Clonal selection and stable cell line establishment in 96-well plate
  • Validation of recombinant antibody expression in 96-well plate and selection of highly expressing clones
  • Clonal expansion and affinity purification of recombinant antibody

 

For Research Use Only. Not for use in clinical diagnostics or therapeutics.

Customers will receive the following deliverables at the end of each project:

  • One stable Sp2/0-Ag14 hybridoma cell line expressing recombinant biosimilar monoclonal antibody with the highest yield
  • 1 mg to 1 g of affinity column purified biosimilar monoclonal antibody
  • Biosimilar IgG heavy chain and light chain cloning into lentiviral vector – 2-3 weeks
  • Lentivirus packaging for biosimilar IgG molecule  – 1-2 weeks
  • Naive Sp2/0-Ag14 hybridoma cell transduction – 1-2 weeks
  • Clonal selection and stable cell line establishment – 3-4 weeks
  • Recombinant antibody expression validation – 2-3 weeks
  • Cell culture expansion and affinity purification – 2-3 weeks

Additional information

Antibody Production Scale

1 mg, 5 mg, 10 mg, 100 mg, 1 g
Isotype

IgG1, IgG2, IgG3, IgG4

Reviews

There are no reviews yet.

Be the first to review “Biosimilar Antibody Production”

Related products

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

Contact us for questions or custom requests!

Email Us